Menu

MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients

O. SLABY, R. LAKOMY, P. FADRUS, R. HRSTKA, L. KREN, E. LZICAROVA, M. SMRCKA, M. SVOBODA, H. DOLEZALOVA, J. NOVAKOVA, D. VALIK, R. VYZULA, J. MICHALEK

Abstract:

MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies showed altered expression levels of several microRNAs in glioblastomas. In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas. MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0,016), miR-222 (p=0,038), miR-181b (p=0,036), miR-181c (p=0,043) and miR-128a (p=0,001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p

Issue: 3/2010

Volume: 2010

Pages: 264 — 269

DOI: 10.4149/neo_2010_03_264

Pubmed

Shopping cart is empty